Vanguard Group
BIOL

Vanguard Group’s Biolase, Inc. BIOL Stock Holding History

Vanguard Group’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,911
Closed -$2.07K – 4461
2024
Q1 		$2.07K Hold
10,911
– – ﹤0.01% 4446
2023
Q4 		$12.2K Buy
+10,911
New +$15.6K ﹤0.01% 4473
2023
Q3 		– Sell
-944
Closed -$6.67K – 4564
2023
Q2 		$6.67K Hold
944
– – ﹤0.01% 4541
2023
Q1 		$26.5K Sell
944
-1,671
-64% -$81.3K ﹤0.01% 4519
2022
Q4 		$170K Sell
2,615
-137
-5% -$19.7K ﹤0.01% 4335
2022
Q3 		$668K Hold
2,752
– – ﹤0.01% 4135
2022
Q2 		$1.26M Hold
2,752
– – ﹤0.01% 4008
2022
Q1 		$2.43M Sell
2,752
-7
-0.3% -$6.46K ﹤0.01% 3884
2021
Q4 		$2.69M Sell
2,759
-30
-1% -$37.8K ﹤0.01% 3928
2021
Q3 		$4.46M Hold
2,789
– – ﹤0.01% 3730
2021
Q2 		$4.87M Sell
2,789
-146
-5% -$271K ﹤0.01% 3622
2021
Q1 		$6.18M Buy
2,935
+2,420
+470% +$5.95M ﹤0.01% 3418
2020
Q4 		$537K Buy
515
+205
+66% +$156K ﹤0.01% 3942
2020
Q3 		$213K Sell
310
-94
-23% -$88.1K ﹤0.01% 3950
2020
Q2 		$468K Buy
404
+14
+4% +$15.9K ﹤0.01% 3782
2020
Q1 		$365K Sell
390
-1
-0.3% -$1.55K ﹤0.01% 3736
2019
Q4 		$540K Sell
391
-1
-0.3% -$1.54K ﹤0.01% 3780
2019
Q3 		$930K Buy
392
+9
+2% +$29.6K ﹤0.01% 3669
2019
Q2 		$1.41M Buy
383
+318
+489% +$1.53M ﹤0.01% 3576
2019
Q1 		$388K Buy
65
+15
+30% +$72.9K ﹤0.01% 3820
2018
Q4 		$125K Sell
50
-98
-66% -$316K ﹤0.01% 3970
2018
Q3 		$768K Buy
148
+30
+25% +$120K ﹤0.01% 3780
2018
Q2 		$356K Buy
118
+1
+0.9% +$3.77K ﹤0.01% 3888
2018
Q1 		$595K Buy
117
+13
+13% +$73K ﹤0.01% 3754
2017
Q4 		$554K Buy
104
+1
+1% +$7.03K ﹤0.01% 3722
2017
Q3 		$774K Sell
103
-18
-15% -$155K ﹤0.01% 3659
2017
Q2 		$1.46M Sell
121
-6
-5% -$89.1K ﹤0.01% 3475
2017
Q1 		$2.14M Buy
127
+1
+0.8% +$18.1K ﹤0.01% 3363
2016
Q4 		$2.21M Sell
126
-2
-2% -$39.6K ﹤0.01% 3332
2016
Q3 		$2.79M Hold
128
– – ﹤0.01% 3266
2016
Q2 		$1.87M Hold
128
– – ﹤0.01% 3405
2016
Q1 		$2.09M Hold
128
– – ﹤0.01% 3360
2015
Q4 		$1.34M Buy
128
+7
+6% +$76.5K ﹤0.01% 3535
2015
Q3 		$1.36M Hold
121
– – ﹤0.01% 3539
2015
Q2 		$2.63M Buy
121
+2
+2% +$48.7K ﹤0.01% 3307
2015
Q1 		$3M Buy
119
+2
+2% +$56.7K ﹤0.01% 3232
2014
Q4 		$3.85M Buy
117
+5
+4% +$156K ﹤0.01% 3026
2014
Q3 		$3.5M Buy
112
+6
+6% +$170K ﹤0.01% 3020
2014
Q2 		$2.93M Sell
106
-4
-4% -$102K ﹤0.01% 3086
2014
Q1 		$3.32M Buy
110
+4
+4% +$140K ﹤0.01% 3007
2013
Q4 		$3.73M Buy
106
+1
+1% +$23.7K ﹤0.01% 2941
2013
Q3 		$2.49M Buy
105
+4
+4% +$129K ﹤0.01% 3052
2013
Q2 		$4.41M Buy
+101
New +$5.65M ﹤0.01% 2741

Other funds holding BIOL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's BIOL Position: Q2 2024 in Review

Vanguard Group sold out of Biolase, Inc. (BIOL) in Q2 2024, closing a stake of 10,911 shares — an estimated $2.07K sold.

Vanguard Group first reported a position in BIOL in Q2 2013 and held it in 43 quarters. The position peaked at $6.18M in Q1 2021. 2 funds tracked by Wall St. Rank hold BIOL as of Q2 2024.

  • Vanguard Group reported no remaining Biolase, Inc. position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 10,911 Biolase, Inc. shares in Q2 2024, an estimated $2.07K.
  • Vanguard Group first reported a position in Biolase, Inc. in Q2 2013 and held it in 43 quarters.
  • Vanguard Group's Biolase, Inc. position peaked at $6.18M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.